ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 77 filers reported holding ONCOCYTE CORP in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $25,902 | -55.3% | 17,384 | -35.2% | 0.00% | – |
Q4 2021 | $58,000 | -18.3% | 26,845 | +35.3% | 0.00% | – |
Q3 2021 | $71,000 | -71.4% | 19,842 | -54.1% | 0.00% | – |
Q2 2021 | $248,000 | +14.8% | 43,240 | +3.8% | 0.00% | – |
Q1 2021 | $216,000 | +101.9% | 41,674 | -6.5% | 0.00% | – |
Q4 2020 | $107,000 | +137.8% | 44,561 | +36.5% | 0.00% | – |
Q3 2020 | $45,000 | -50.0% | 32,641 | +17.3% | 0.00% | – |
Q2 2020 | $90,000 | +2900.0% | 27,819 | +2178.4% | 0.00% | – |
Q2 2018 | $3,000 | -70.0% | 1,221 | -73.4% | 0.00% | – |
Q1 2018 | $10,000 | +11.1% | 4,589 | +135.8% | 0.00% | – |
Q4 2017 | $9,000 | -35.7% | 1,946 | +2.7% | 0.00% | – |
Q3 2017 | $14,000 | -12.5% | 1,894 | -38.9% | 0.00% | – |
Q2 2017 | $16,000 | +166.7% | 3,102 | +183.5% | 0.00% | – |
Q1 2017 | $6,000 | -14.3% | 1,094 | 0.0% | 0.00% | – |
Q4 2016 | $7,000 | -22.2% | 1,094 | -42.4% | 0.00% | – |
Q3 2016 | $9,000 | +28.6% | 1,899 | 0.0% | 0.00% | – |
Q2 2016 | $7,000 | -61.1% | 1,899 | -49.4% | 0.00% | – |
Q1 2016 | $18,000 | – | 3,753 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |